Specific genes associated with triple-negative breast cancer risk have been identified by multigene hereditary cancer panel testing.
Browsing: Disease Area > Breast
A Phase 1b clinical trial investigating tucatinib combined with ado-trastuzumab emtansine in advanced ERBB2/HER2-positive metastatic breast cancer has yielded encouraging results.
The Phase III IMpassion130 study, investigating TECENTRIQ® plus Abraxane® for triple-negative breast cancer, has met its progression-free survival endpoint.
In a medical breakthrough, a new approach to immunotherapy has led to complete regression of breast cancer in a patient unresponsive to all other treatments.
The Phase III TAILORx clinical trial results indicate that most women with a specific early-stage breast cancer and midrange score on a gene expression assay do not need chemotherapy after surgery.
Results from a Phase lll clinical trial demonstrate the success of a new targeted medicine, taselisib, in treating advanced breast cancer.
A team of researchers have identified the cause of resistance to breakthrough breast and ovarian cancer drugs.
The primary objective of TAILORx is to more precisely determine the effect of chemotherapy, if any, for women with node-negative, hormone receptor-positive disease and Oncotype DX Breast Recurrence Score® results of 11–25.